{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:19:30Z","timestamp":1759940370708,"version":"3.40.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.leukres.2016.09.016","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T04:47:31Z","timestamp":1474346851000},"page":"63-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"50","author":[{"given":"Sara E.F.","family":"Kost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.J.","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9lise","family":"LaBossi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xibiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"Queau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7415-8818","authenticated-orcid":false,"given":"Versha","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer B.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Katyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.09.016_bib0005","series-title":"Wintrobe\u2019s Clinical Hematology","first-page":"1888","article-title":"Chronic lymphocytic leukemia","author":"Johnston","year":"2013"},{"key":"10.1016\/j.leukres.2016.09.016_bib0010","first-page":"1","article-title":"Initial treatment of CLL: integrating biology and functional status","volume":"714","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2016.09.016_bib0015","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/cncr.28318","article-title":"Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia","volume":"119","author":"Strati","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2016.09.016_bib0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/modpathol.2011.158","article-title":"Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"25","author":"Zhou","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.leukres.2016.09.016_bib0025","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"May (9)","key":"10.1016\/j.leukres.2016.09.016_bib0030","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/cncr.25028","article-title":"Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia","volume":"116","author":"Kay","year":"2010","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2016.09.016_bib0035","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/cncr.22662","article-title":"Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia","volume":"109","author":"Shanafelt","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2016.09.016_bib0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2016.09.016_bib0045","article-title":"Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel\u2014an update","author":"Cheson","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"24","key":"10.1016\/j.leukres.2016.09.016_bib0050","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1158\/1078-0432.CCR-08-3041","article-title":"Bendamustine in B-cell malignancies: the new 46-year-old kid on the block","volume":"15","author":"Gandhi","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.leukres.2016.09.016_bib0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12000","article-title":"Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial","volume":"159","author":"Knauf","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"26","key":"10.1016\/j.leukres.2016.09.016_bib0060","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2016.09.016_bib0065","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00277-012-1660-6","article-title":"Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia","volume":"92","author":"Niederle","year":"2013","journal-title":"Ann. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2016.09.016_bib0070","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/sj.leu.2402651","article-title":"In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia","volume":"16","author":"Schw\u00e4nen","year":"2002","journal-title":"Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK"},{"issue":"21","key":"10.1016\/j.leukres.2016.09.016_bib0075","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1158\/1078-0432.CCR-08-0388","article-title":"Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling","volume":"14","author":"Rou\u00e9","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"50","key":"10.1016\/j.leukres.2016.09.016_bib0080","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1038\/onc.2008.316","article-title":"Nucleoside analogs: molecular mechanisms signaling cell death","volume":"27","author":"Ewald","year":"2008","journal-title":"Oncogene"},{"issue":"Suppl 2 (June)","key":"10.1016\/j.leukres.2016.09.016_bib0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428194.2011.570394","article-title":"Mechanism of action of pentostatin and cladribine in hairy cell leukemia","volume":"52","author":"Johnston","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2016.09.016_bib0090","first-page":"S140","article-title":"Combination therapy with nucleoside analogs and alkylating agents","volume":"8","author":"Johnston","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.09.016_bib0095","first-page":"3981","article-title":"Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine LSI78Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2 \u2019 -deoxycoformycin and deoxyadenosine in vitro","volume":"48","author":"Begleiter","year":"1988","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.leukres.2016.09.016_bib0100","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.leukres.2016.09.016_bib0105","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1158\/1078-0432.CCR-14-0624","article-title":"On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells","volume":"20","author":"Gehrke","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"51","key":"10.1016\/j.leukres.2016.09.016_bib0110","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1038\/sj.onc.1207004","article-title":"Role of the TRAIL\/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia","volume":"22","author":"Johnston","year":"2003","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.leukres.2016.09.016_bib0115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nn.3715","article-title":"Aberrant topoisomerase-1 DNA lesions are pathogenic in neurodegenerative genome instability syndromes","volume":"17","author":"Katyal","year":"2014","journal-title":"Nat. Neurosci."},{"issue":"5","key":"10.1016\/j.leukres.2016.09.016_bib0120","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2141.2008.07418.x","article-title":"Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro","volume":"143","author":"Amrein","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"September (3)","key":"10.1016\/j.leukres.2016.09.016_bib0125","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.leukres.2016.09.016_bib0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00432-002-0331-8","article-title":"Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines","volume":"128","author":"Konstantinov","year":"2002","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.09.016_bib0135","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","article-title":"Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines","volume":"7","author":"Strumberg","year":"1996","journal-title":"Anticancer Drugs"},{"issue":"26","key":"10.1016\/j.leukres.2016.09.016_bib0140","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2016.09.016_bib0145","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.leukres.2011.01.004","article-title":"Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy","volume":"35","author":"Amrein","year":"2011","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2016.09.016_bib0150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11912-007-0048-6","article-title":"The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance","volume":"9","author":"Sampath","year":"2007","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"10.1016\/j.leukres.2016.09.016_bib0155","first-page":"2055","article-title":"DNA repair and cellular resistance to alkylating agents in chronic lymphocytic leukemia","volume":"3","author":"M\u00fcller","year":"1997","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.leukres.2016.09.016_bib0160","doi-asserted-by":"crossref","first-page":"e40342","DOI":"10.1371\/journal.pone.0040342","article-title":"Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine","volume":"7","author":"Beeharry","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2016.09.016_bib0165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00686487","article-title":"Factors influencing the inhibition of repair of irradiation-induced DNA damage by 2\u2032-deoxycoformycin and deoxyadenosine","volume":"30","author":"Begleiter","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"24","key":"10.1016\/j.leukres.2016.09.016_bib0170","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood-2013-12-541433","article-title":"Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells","volume":"123","author":"El-Mabhouh","year":"2014","journal-title":"Blood"},{"issue":"0006\u20134971","key":"10.1016\/j.leukres.2016.09.016_bib0175","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537","article-title":"Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria","volume":"96","author":"Genini","year":"2000","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T13:12:37Z","timestamp":1718802757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616302028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":35,"alternative-id":["S0145212616302028"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.09.016","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}